A company that has stopped supplying raw materials refuses to fulfill its obligation of selection in centralized procurement

Text | Wind Hill

On April 26, the Zhejiang Pharmaceutical Equipment Procurement Center issued an announcement stating that the cefmetazole sodium for injection produced by Suzhou Dawnrays Pharmaceutical Co.

The first batch of pharmaceutical procurement in Zhejiang Province was announced on January 11 and the results were officially implemented on March 15.

However, a few days ago, Zhejiang Pharmaceutical Equipment Procurement Center issued a document stating that the "Cefmetazole Sodium for Injection" (powder injection, specification 1.

1.

2.

3.

It also stated that it will further strengthen the supervision and management of online purchases and transactions of online trading products, and ensure the normal and orderly supply of drugs in Zhejiang Province through face-to-face interviews, letter inquiries, and notifications to enterprises and medical and health institutions involved in abnormal purchases.

At the same time, according to Zhejiang Province’s drug procurement documents, in order to participate in centralized procurement, companies must have no serious illegal records within 2 years, such as giving rebates or other improper benefits in the purchase and sale of medicines, tax-related violations, monopoly behavior, and non-compliance Behaviors that are contrary to honesty and credibility, such as fair price behavior, disrupting the order of centralized procurement, and maliciously violating contractual agreements.